Introduction: Target driven drug discovery is a long and arduous task requiring a huge
investment of time, energy and resources. Therefore, it is very important to select targets …

New drugs that retain potency against multidrug/extensively drug-resistant strains of
Mycobacterium tuberculosis, with the additional benefit of a shortened treatment duration …

More than two decades have elapsed since the publication of the first genome sequence of
Mycobacterium tuberculosis (Mtb) which, shortly thereafter, enabled methods to determine …

Highlights•High-throughput phenotypic screens have broadened the target space for new
TB drugs.•TB drug efficacy can be potentiated by targeting non-essential bacillary …

Highlights•Target promiscuity is merely a reflection of bias in screening
assays.•Promiscuous targets represent pathogen's vulnerabilities both in vitro and in …

Tuberculosis (TB) is an infectious disease, infecting a quarter of world's population. Drug
resistant TB further exacerbates the grim scenario of the drying TB drug discovery pipeline …

Tuberculosis (TB) is a severe infectious disease worldwide. The increasing emergence of
drug‐resistant Mycobacterium tuberculosis (Mtb) has markedly hampered TB control …

There is an urgent need for new drugs to treat tuberculosis. During the last forty years the
only drugs to have been developed are variations on existing ones, but new drug …

Tuberculosis is an ever evolving infectious disease that still claims about 1.8 million human
lives each year around the globe. Although modern chemotherapy has played a pivotal role …

The recent past has experienced a renaissance in tuberculosis (TB) research. New
molecular biology reagents and genetic tools have been developed and whole genome …